| Summary: | The probiotic strain <i>Lactobacillus johnsonii</i> CNCM I-4884 exhibits anti-<i>Giardia</i> activity in vitro and in vivo in a murine model of giardiasis. The aim of this study was the identification and characterization of the probiotic potential of <i>L. johnsonii</i> CNCM I-4884, as well as its safety assessment. This strain was originally classified as <i>Lactobacillus gasseri</i> based on 16S gene sequence analysis. Whole genome sequencing led to a reclassification as <i>L. johnsonii</i>. A genome-wide search for biosynthetic pathways revealed a high degree of auxotrophy, balanced by large transport and catabolic systems. The strain also exhibits tolerance to low pH and bile salts and shows strong bile salt hydrolase (BSH) activity. Sequencing results revealed the absence of antimicrobial resistance genes and other virulence factors. Phenotypic tests confirm that the strain is susceptible to a panel of 8 antibiotics of both human and animal relevance. Altogether, the in silico and in vitro results confirm that <i>L. johnsonii</i> CNCM I-4884 is well adapted to the gastrointestinal environment and could be safely used in probiotic formulations.
|
|---|